Literature DB >> 18829136

Whole brain atrophy rate predicts progression from MCI to Alzheimer's disease.

Gabriela Spulber1, Eini Niskanen, Stuart MacDonald, Oded Smilovici, Kewei Chen, Eric M Reiman, Anne M Jauhiainen, Merja Hallikainen, Susanna Tervo, Lars-Olof Wahlund, Ritva Vanninen, Miia Kivipelto, Hilkka Soininen.   

Abstract

For both clinical and research reasons, it is essential to identify which mild cognitive impairment (MCI) subjects subsequently progress to Alzheimer's disease (AD). The prediction may be facilitated by accelerated whole brain atrophy exhibited by AD subjects. Iterative principal component analysis (IPCA) was used to characterize whole brain atrophy rates using sequential MRI scans for 102 MCI subjects from the Kuopio University Hospital. We modelled the likelihood of progression to probable AD, and found that each additional percent of annualized whole brain atrophy rate was associated with a higher odds ratio (OR) of progression (OR=1.30, p=0.01, 95% CI=1.05-1.60). Our study demonstrates an association between whole brain atrophy rate and subsequent rate of clinical progression from MCI to AD. These findings suggest that IPCA could be an effective brain-imaging marker of progression to AD and useful tool for the evaluation of disease-modifying treatments. Copyright 2008 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2008        PMID: 18829136     DOI: 10.1016/j.neurobiolaging.2008.08.018

Source DB:  PubMed          Journal:  Neurobiol Aging        ISSN: 0197-4580            Impact factor:   4.673


  19 in total

Review 1.  Progression of atrophy in Alzheimer's disease and related disorders.

Authors:  Jennifer L Whitwell
Journal:  Neurotox Res       Date:  2010-03-30       Impact factor: 3.911

2.  Linking biological and cognitive aging: toward improving characterizations of developmental time.

Authors:  Stuart W S MacDonald; Correne A DeCarlo; Roger A Dixon
Journal:  J Gerontol B Psychol Sci Soc Sci       Date:  2011-07       Impact factor: 4.077

Review 3.  BioAge: toward a multi-determined, mechanistic account of cognitive aging.

Authors:  Correne A DeCarlo; Holly A Tuokko; Dorothy Williams; Roger A Dixon; Stuart W S MacDonald
Journal:  Ageing Res Rev       Date:  2014-09-30       Impact factor: 10.895

4.  Correlations between FDG PET glucose uptake-MRI gray matter volume scores and apolipoprotein E ε4 gene dose in cognitively normal adults: a cross-validation study using voxel-based multi-modal partial least squares.

Authors:  Kewei Chen; Napatkamon Ayutyanont; Jessica B S Langbaum; Adam S Fleisher; Cole Reschke; Wendy Lee; Xiaofen Liu; Gene E Alexander; Dan Bandy; Richard J Caselli; Eric M Reiman
Journal:  Neuroimage       Date:  2012-02-12       Impact factor: 6.556

5.  Cerebral atrophy, apolipoprotein E varepsilon4, and rate of decline in everyday function among patients with amnestic mild cognitive impairment.

Authors:  Ozioma C Okonkwo; Michael L Alosco; Beth A Jerskey; Lawrence H Sweet; Brian R Ott; Geoffrey Tremont
Journal:  Alzheimers Dement       Date:  2010-09       Impact factor: 21.566

6.  Targeting mitochondrial bioenergetics for Alzheimer's prevention and treatment.

Authors:  Jia Yao; Roberta Diaz Brinton
Journal:  Curr Pharm Des       Date:  2011       Impact factor: 3.116

Review 7.  Shift in brain metabolism in late onset Alzheimer's disease: implications for biomarkers and therapeutic interventions.

Authors:  Jia Yao; Jamaica R Rettberg; Lauren P Klosinski; Enrique Cadenas; Roberta Diaz Brinton
Journal:  Mol Aspects Med       Date:  2011-10-21

Review 8.  Functional and structural MR imaging in neuropsychiatric disorders, Part 1: imaging techniques and their application in mild cognitive impairment and Alzheimer disease.

Authors:  S Mueller; D Keeser; M F Reiser; S Teipel; T Meindl
Journal:  AJNR Am J Neuroradiol       Date:  2011-12-15       Impact factor: 3.825

Review 9.  Estrogen regulation of mitochondrial bioenergetics: implications for prevention of Alzheimer's disease.

Authors:  Jia Yao; Roberta Diaz Brinton
Journal:  Adv Pharmacol       Date:  2012

Review 10.  Neuroketotherapeutics: A modern review of a century-old therapy.

Authors:  Scott J Koppel; Russell H Swerdlow
Journal:  Neurochem Int       Date:  2017-06-01       Impact factor: 3.921

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.